Testing a new immune therapy for advanced prostate and kidney cancers

Plain-English translation of NCT03972657 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing (also called Nezastomig), a new medication designed to boost your immune system to fight advanced prostate cancer or kidney cancer. Researchers want to learn if this treatment works better when given by itself or combined with another immune-boosting drug called . The study has two stages: first, doctors will find the safest dose, and then they'll test whether that dose actually shrinks tumors.

Some patients with advanced prostate or kidney cancer stop responding to current standard treatments, and their cancer continues to grow. This medication works in a new way to help the immune system recognize and destroy cancer cells, offering hope for people who have exhausted other options.

Do you qualify?

You likely qualify if…

you have been diagnosed with metastatic castration-resistant prostate cancer (cancer that has spread and no longer responds to hormone therapy) or metastatic clear-cell kidney cancer
you have already received at least two prior lines of standard cancer treatment without stopping the cancer's growth
you have a measurable tumor that doctors can track on scans
you are generally in good enough health to tolerate a clinical trial, as determined by your doctor
you are willing to receive the medication through injections or infusions at a research center

You likely don't qualify if…

you have received recent cancer treatment within 3 weeks or other immunotherapy treatments within 5 half-lives before starting the study
you have had any prior treatments that directly target PSMA (except for specific radioactive PSMA therapies already approved)
you are currently taking high-dose corticosteroids or have an active autoimmune disease requiring ongoing immune-suppressing medications
you have an active or uncontrolled infection, including untreated HIV, hepatitis B, or hepatitis C
you have had seizures, encephalitis, meningitis, or other serious neurological conditions within the past year

What participation looks like

You will visit a research hospital or clinic regularly for check-ins, blood tests, and scans to monitor how your cancer is responding. The study has two phases: first, researchers determine the safest dose by gradually increasing it in small groups of patients; then, larger groups receive the established dose to see if it shrinks tumors. You'll receive the medication through injections or infusions, and doctors will carefully watch for side effects throughout your participation.

AI-generated summary from trial data · Jul 21, 2026 · Not medical advice

Testing a new immune therapy for advanced prostate and kidney cancers

What is this trial?

Do you qualify?

What participation looks like

Trial locations(24 sites)